Open Orphan plc
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker an… Read more
Open Orphan plc (OPORF) - Net Assets
Latest net assets as of June 2025: $43.63 Million USD
Based on the latest financial reports, Open Orphan plc (OPORF) has net assets worth $43.63 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($85.67 Million) and total liabilities ($42.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $43.63 Million |
| % of Total Assets | 50.93% |
| Annual Growth Rate | 59.37% |
| 5-Year Change | 100.36% |
| 10-Year Change | 491.59% |
| Growth Volatility | 518.97 |
Open Orphan plc - Net Assets Trend (2011–2024)
This chart illustrates how Open Orphan plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Open Orphan plc (2011–2024)
The table below shows the annual net assets of Open Orphan plc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $44.67 Million | +30.15% |
| 2023-12-31 | $34.33 Million | +69.78% |
| 2022-12-31 | $20.22 Million | -2.23% |
| 2021-12-31 | $20.68 Million | -7.25% |
| 2020-12-31 | $22.30 Million | +679.07% |
| 2019-12-31 | $2.86 Million | -27.17% |
| 2018-12-31 | $3.93 Million | -49.44% |
| 2017-12-31 | $7.77 Million | -12.60% |
| 2016-12-31 | $8.89 Million | +17.75% |
| 2015-12-31 | $7.55 Million | +436.40% |
| 2014-12-31 | $1.41 Million | +133.18% |
| 2013-12-31 | $603.77K | -70.83% |
| 2012-12-31 | $2.07 Million | +1883.44% |
| 2011-12-31 | $104.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Open Orphan plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8705.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $48.81 Million | 109.25% |
| Common Stock | $680.00K | 1.52% |
| Other Comprehensive Income | $-5.33 Million | -11.93% |
| Other Components | $516.00K | 1.16% |
| Total Equity | $44.67 Million | 100.00% |
Open Orphan plc Competitors by Market Cap
The table below lists competitors of Open Orphan plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OrganiGram Holdings Inc
NASDAQ:OGI
|
$135.42 Million |
|
NervGen Pharma Corp
OTCQB:NGENF
|
$135.47 Million |
|
UNISEM Co. Ltd
KQ:036200
|
$135.48 Million |
|
Richardson Electronics Ltd
NASDAQ:RELL
|
$135.48 Million |
|
Vinte Viviendas Integrales S.A.B. de C.V
MX:VINTE
|
$135.41 Million |
|
Global Standard Technology Limited
KQ:083450
|
$135.39 Million |
|
Avita Medical Ltd
NASDAQ:RCEL
|
$135.36 Million |
|
Hi-Lex Corporation
PINK:HLXFF
|
$135.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Open Orphan plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,326,000 to 44,675,000, a change of 10,349,000 (30.1%).
- Net income of 10,652,000 contributed positively to equity growth.
- Dividend payments of 1,358,000 reduced retained earnings.
- Other comprehensive income decreased equity by 6,637,000.
- Other factors increased equity by 7,692,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $10.65 Million | +23.84% |
| Dividends Paid | $1.36 Million | -3.04% |
| Other Comprehensive Income | $-6.64 Million | -14.86% |
| Other Changes | $7.69 Million | +17.22% |
| Total Change | $- | 30.15% |
Book Value vs Market Value Analysis
This analysis compares Open Orphan plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 46.23x to 3.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.01 | $0.24 | x |
| 2012-12-31 | $0.20 | $0.24 | x |
| 2013-12-31 | $0.03 | $0.24 | x |
| 2014-12-31 | $0.04 | $0.24 | x |
| 2015-12-31 | $0.18 | $0.24 | x |
| 2016-12-31 | $0.14 | $0.24 | x |
| 2017-12-31 | $0.12 | $0.24 | x |
| 2018-12-31 | $0.05 | $0.24 | x |
| 2019-12-31 | $0.02 | $0.24 | x |
| 2020-12-31 | $0.04 | $0.24 | x |
| 2021-12-31 | $0.03 | $0.24 | x |
| 2022-12-31 | $0.03 | $0.24 | x |
| 2023-12-31 | $0.05 | $0.24 | x |
| 2024-12-31 | $0.06 | $0.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Open Orphan plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.84%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.98%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 1.99x
- Recent ROE (23.84%) is above the historical average (17.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 968.80% | 35.21% | 1.65x | 16.69x | $1.00 Million |
| 2012 | -46.34% | -43.73% | 0.61x | 1.74x | $-1.17 Million |
| 2013 | -249.65% | -88.45% | 0.86x | 3.29x | $-1.57 Million |
| 2014 | -121.86% | -31.39% | 0.82x | 4.75x | $-1.30 Million |
| 2015 | 0.15% | 0.13% | 0.75x | 1.54x | $-719.96K |
| 2016 | 5.10% | 2.97% | 1.22x | 1.41x | $-435.75K |
| 2017 | -17.57% | -8.84% | 1.43x | 1.39x | $-2.14 Million |
| 2018 | -109.54% | -34.30% | 1.61x | 1.99x | $-4.70 Million |
| 2019 | -197.58% | -172.19% | 0.36x | 3.17x | $-5.94 Million |
| 2020 | -48.40% | -52.38% | 0.42x | 2.18x | $-13.02 Million |
| 2021 | -0.36% | -0.20% | 0.87x | 2.04x | $-2.14 Million |
| 2022 | -3.84% | -1.53% | 0.99x | 2.54x | $-2.80 Million |
| 2023 | 46.95% | 28.75% | 0.67x | 2.42x | $12.68 Million |
| 2024 | 23.84% | 16.98% | 0.71x | 1.99x | $6.18 Million |
Industry Comparison
This section compares Open Orphan plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Open Orphan plc (OPORF) | $43.63 Million | 968.80% | 0.96x | $135.41 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |